NASDAQ:PHAS

PhaseBio Pharmaceuticals Earnings Date, Estimates & Call Transcripts (2022)

$0.68

+0.03 (+4.62%)

(As of 06/24/2022 04:00 PM ET)

Add

Compare

Today's Range: $0.65
▼
$0.72
50-Day Range: $0.52
▼
$1.39
52-Week Range: $0.50
▼
$4.10

Volume: 626,389 shs
Average Volume: 474,408 shs
Market Capitalization: $33.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $12.50

Upcoming Earnings Date: Aug. 11Estimated
Actual EPS (May. 16): -$0.23 Beat By $0.44
Consensus EPS (May. 16): -$0.67
Last Year's Q2 EPS (5/13/2021): -$0.87

Earnings Per Share Revenue

PHAS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

PHAS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

PhaseBio Pharmaceuticals Earnings Estimates

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2022	1	($0.50)	($0.50)	($0.50)
Q2 2022	1	($0.79)	($0.79)	($0.79)
Q3 2022	1	($0.74)	($0.74)	($0.74)
Q4 2022	1	($0.83)	($0.83)	($0.83)
FY 2022	4	($2.86)	($2.86)	($2.86)
Q1 2023	1	($0.31)	($0.31)	($0.31)
Q2 2023	1	($0.30)	($0.30)	($0.30)
Q3 2023	1	($0.30)	($0.30)	($0.30)
Q4 2023	1	($0.25)	($0.25)	($0.25)
FY 2023	4	($1.16)	($1.16)	($1.16)

PHAS Earnings Date and Information

PhaseBio Pharmaceuticals last posted its earnings data on May 16th, 2022. The reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.44. The company had revenue of $0.12 million for the quarter, compared to the consensus estimate of $5.83 million. PhaseBio Pharmaceuticals has generated ($2.39) earnings per share over the last year (($2.39) diluted earnings per share). Earnings for PhaseBio Pharmaceuticals are expected to grow in the coming year, from ($1.64) to ($1.25) per share. PhaseBio Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off prior year's report dates.

PhaseBio Pharmaceuticals Earnings History by Quarter

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
8/11/2022 (Estimated)
5/16/2022	Q1 2022	($0.67)	($0.23)	+$0.44	($0.23)	$5.83 million	$0.12 million
3/24/2022	Q4 2021	($0.39)	($0.90)	($0.51)	($0.90)	$4.92 million	$0.16 million
11/10/2021	9/30/2021	($0.59)	($0.66)	($0.07)	($0.66)	$2.67 million	$0.34 million
8/12/2021	6/30/2021	($0.46)	($0.60)	($0.14)	($0.60)		$10.34 million
5/13/2021	3/31/2021	($0.73)	($0.87)	($0.14)	($0.87)
3/14/2021	12/31/2020	($0.70)	($1.03)	($0.33)	($1.03)
11/12/2020	9/30/2020	($0.77)	($0.86)	($0.09)	($0.86)
8/11/2020	Q2 2020	($0.52)	($0.98)	($0.46)	($0.98)
5/12/2020	Q1 2020	($0.4220)	($0.52)	($0.0980)	($0.52)	$0.38 million	$0.32 million
3/30/2020	12/31/2019	($0.40)	($0.39)	+$0.01	($0.39)	$0.40 million	$0.76 million
11/14/2019	Q3	($0.36)	($0.40)	($0.04)	($0.40)	$0.35 million	$0.24 million
8/13/2019	Q2 2019	($0.35)	($0.330510)	+$0.019490	($0.33)	$0.13 million	$0.70 million
5/9/2019	3/31/2019	($0.44)	($0.30)	+$0.14	($0.30)	$0.12 million	$0.65 million
3/26/2019	12/31/2018	($0.29)	($0.26)	+$0.03	($0.26)		$0.26 million
11/29/2018	Q3	($0.22)	($10.45)	($10.23)	($10.45)		$0.41 million

PhaseBio Pharmaceuticals Earnings - Frequently Asked Questions

When is PhaseBio Pharmaceuticals's earnings date?: PhaseBio Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 11th, 2022 based off last year's report dates. Learn more on PHAS's earnings history.
Did PhaseBio Pharmaceuticals beat their earnings estimates last quarter?: In the previous quarter, PhaseBio Pharmaceuticals (NASDAQ:PHAS) reported ($0.23) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.67) by $0.44. Learn more on analysts' earnings estimate vs. PHAS's actual earnings.

How much revenue does PhaseBio Pharmaceuticals generate each year?: PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a recorded annual revenue of $10.83 million.
How much profit does PhaseBio Pharmaceuticals generate each year?: PhaseBio Pharmaceuticals (NASDAQ:PHAS) has a recorded net income of -$131.07 million. PHAS has generated -$2.39 earnings per share over the last four quarters.
What is PhaseBio Pharmaceuticals's EPS forecast for next year?: PhaseBio Pharmaceuticals's earnings are expected to grow from ($1.64) per share to ($1.25) per share in the next year.

This page (NASDAQ:PHAS) was last updated on 6/26/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources